Evaluation of Cryoprotection Induced Nail Toxicity Docetaxel Low Cumulative Dose

Inclusion criteria

• upper age to 18 years
• mammary adenocarcinoma nonmetastatic and histologically proven
• wait under an adjuvant or neoadjuvant chemotherapy according to the following conventional scheme: 3 cycles of F5-Fluorouracil, epirubicin and cyclophosphamide 100 (500 or 5-Fluorouracil 600 mg / m² J1, Epirubicin 100 mg / m² J1, Cyclophosphamide 500 or 600 mg / m² J1 or 3 cycles of Epiribucin and Cyclophosphamide 100) followed by 3 cycles of docetaxel, 100 mg / m², +/- trastuzumab if Her2+++
• Patient with the capacity/faculties to understand a newsletter and sign an informed consent
• Patient receiving social coverage
• Patient who can be treated and followed in the center for a period of at least one year
• WHO scale 0 or 1

Exclusion criteria

• Age below 18 years
• Diseases of the scalp or whatever hair-showing against helmet or alopecia
• Using pre nail resin before and per chemotherapy
• mammary adenocarcinoma stage IV
• Indication of docetaxel for cancer of another organ than breast
• Treatment processing or programmed during chemotherapy with an innovative molecule being evaluated
• Raynaud's syndrome, cold agglutinin disease, cryoglobulinemia and cryofibrinogenemia.
• Uncontrolled severe arterial disease.
• Presence of a device> grade 1 neuropathy before the start of chemotherapy
• Patient unable to submit the protocol followed for psychological, social, family or geographical
• Patient with an incompatible underlying disease or concomitant with the inclusion in the trial, whether psychiatric or somatic
• Patient trust, guardianship, under legal protection measure, deprived of freedom
• Male
• Criteria for non randomization (before the first course of docetaxel) :

• Presence of peripheral neuropathy> grade 1 after the first 3 cycles of 5-Fluorouracil, epirubicin and cyclophosphamide 100.
• Presence of a nail or skin toxicity> grade 1 after 3 cycles of 5-Fluorouracil, epirubicin and cyclophosphamide 100.